These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37232341)

  • 21. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
    Chism DD; De Silva D; Whang YE
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1369-78. PubMed ID: 24927631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L; Schweizer MT
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
    Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
    Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
    Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
    Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
    Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 30. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
    Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
    [No Abstract]   [Full Text] [Related]  

  • 31. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
    Sowalsky AG; Ye H; Bhasin M; Van Allen EM; Loda M; Lis RT; Montaser-Kouhsari L; Calagua C; Ma F; Russo JW; Schaefer RJ; Voznesensky OS; Zhang Z; Bubley GJ; Montgomery B; Mostaghel EA; Nelson PS; Taplin ME; Balk SP
    Cancer Res; 2018 Aug; 78(16):4716-4730. PubMed ID: 29921690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells.
    Lee E; Ha S; Logan SK
    PLoS One; 2015; 10(10):e0141589. PubMed ID: 26509262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
    Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
    Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
    Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
    Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.